Evidence map›Paper›PMID 32629766›Full record

ArticleCancers2020

Calcium Signaling Alterations Caused by Epigenetic Mechanisms in Pancreatic Cancer: From Early Markers to Prognostic Impact.

Cleandra Gregório, Sheila Coelho Soares-Lima, Bárbara Alemar, Mariana Recamonde-Mendoza, Diego Camuzi, Paulo Thiago de Souza-Santos, Raquel Rivero, Simone Machado, Alessandro Osvaldt, Patricia Ashton-Prolla and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Transcriptional and epigenetic landscape of CaJournal of cell communication and signaling · 2021
    Article
  9. Review
  10. A novel strategy for treating cancer: understanding the role of CaExploration of targeted anti-tumor therapy · 2021
    Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Cleandra GregórioLaboratório de Medicina Genômica, Centro de Pesquisa Experimental, Hospital de Clínicas de Porto Alegre, Porto Alegre 90035-007, Brazil.ORCID 0000-0002-6476-219X
Sheila Coelho Soares-LimaPrograma de Carcinogênese Molecular, Instituto Nacional de Câncer, Rio de Janeiro 20231-050, Brazil.ORCID 0000-0002-6742-3708
Bárbara AlemarLaboratório de Medicina Genômica, Centro de Pesquisa Experimental, Hospital de Clínicas de Porto Alegre, Porto Alegre 90035-007, Brazil.
Mariana Recamonde-MendozaInstituto de Informática, Universidade Federal do Rio Grande do Sul, Porto Alegre 91501-970, Brazil.ORCID 0000-0003-2800-1032
Diego CamuziPrograma de Carcinogênese Molecular, Instituto Nacional de Câncer, Rio de Janeiro 20231-050, Brazil.ORCID 0000-0002-3807-3796
Paulo Thiago de Souza-SantosLaboratório de Hanseníase, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-360, Brazil.ORCID 0000-0002-0493-6661
Raquel RiveroServiço de Patologia, Hospital de Clínicas de Porto Alegre, Porto Alegre 90035-007, Brazil.
Simone MachadoServiço de Patologia, Hospital de Clínicas de Porto Alegre, Porto Alegre 90035-007, Brazil.
Alessandro OsvaldtGrupo de Vias Biliares e Pâncreas, Cirurgia do Aparelho Digestivo, Hospital de Clínicas de Porto Alegre, Porto Alegre 90035-007, Brazil.ORCID 0000-0002-5863-6656
Patricia Ashton-ProllaLaboratório de Medicina Genômica, Centro de Pesquisa Experimental, Hospital de Clínicas de Porto Alegre, Porto Alegre 90035-007, Brazil.ORCID 0000-0002-5093-4739
Luis Felipe Ribeiro PintoPrograma de Carcinogênese Molecular, Instituto Nacional de Câncer, Rio de Janeiro 20231-050, Brazil.
Universidade Federal do Rio Grande do Sul · BRHospital de Clínicas de Porto Alegre · BRInstituto Nacional de Câncer - INCA · BRFundação Oswaldo Cruz · BRUniversidade do Estado do Rio de Janeiro · BR

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 424646/2016-1Fundação de Amparo a Pesquisa do Estado do Rio de Janeiro E-26/010.001856/2015Fundo de Incentivo à Pesquisa - FIPE, Hospital de Clínicas de Porto Alegre 14-0526Swiss Bridge Foundation 302404
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with high mortality rates. PDAC initiation and progression are promoted by genetic and epigenetic dysregulation. Here, we aimed to characterize the PDAC DNA methylome in search of novel altered pathways associated with tumor development. We examined the genome-wide DNA methylation profile of PDAC in an exploratory cohort including the comparative analyses of tumoral and non-tumoral pancreatic tissues (PT). Pathway enrichment analysis was used to choose differentially methylated (DM) CpGs with potential biological relevance. Additional samples were used in a validation cohort. DNA methylation impact on gene expression and its association with overall survival (OS) was investigated from PDAC TCGA (The Cancer Genome Atlas) data. Pathway analysis revealed DM genes in the calcium signaling pathway that is linked to the key pathways in pancreatic carcinogenesis. DNA methylation was frequently correlated with expression, and a subgroup of calcium signaling genes was associated with OS, reinforcing its probable phenotypic effect. Cluster analysis of PT samples revealed that some of the methylation alterations observed in the Calcium signaling pathway seemed to occur early in the carcinogenesis process, a finding that may open new insights about PDAC tumor biology.

Indexed as

calcium signaling pathwayDNA methylationearly methylation alterationspancreatic ductal adenocarcinomaprognostic biomarkers

Identifiers

PMID32629766
PMCPMC7407273
OpenAlexW3037191163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.